Moreover, PRMT5 inhibition resulted in a further decrease in cell viability, as well as a further increase in apoptosis and G2 phase cell cycle arrest in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells. This evidence concerns the gene PRMT5 and colorectal carcinoma.